Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.
Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Private Equity Round in 2022
Saluda Medical Pty Ltd. is a medical device company focused on developing innovative solutions for the neuromodulation industry. The firm is known for its investigational device, Evoke, which features a closed-loop spinal cord stimulation system. This technology measures the spinal cord's response to stimulation and adjusts the stimulation parameters in real-time to optimize therapeutic outcomes for patients. Founded in 2010 and headquartered in Artarmon, Australia, with additional offices in Minnesota and the United Kingdom, Saluda Medical aims to provide effective treatment for chronic neuropathic pain. The company's unique approach involves monitoring each patient's neural fingerprint to automatically tailor electrical stimulation, ensuring that therapy is customized to meet individual needs. Saluda Medical's commitment to advancing medical technology is underpinned by a strong foundation of scientific research and a team of experienced professionals.
Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platform’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.
Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Laronde is focused on developing innovative therapeutics using its proprietary Endless RNA™ (eRNA) platform, which allows for the modulation of human biology through uniquely engineered RNA. This technology enables the expression of diverse proteins within the body while being persistent, non-immunogenic, and suitable for repeat dosing. Additionally, it provides flexibility in formulation and delivery, making it a promising foundation for new medicines. Founded in 2017 by Flagship Labs, Laronde is rapidly scaling its operations to support the simultaneous development of various programs targeting multiple disease areas, aiming to create more predictable and impactful treatments in the healthcare sector.
Ring Therapeutics, Inc. is a biotechnology company that specializes in developing gene therapies through its innovative viral vector platform, Anellovector. This platform leverages the human commensal virome to create redosable and targetable DNA therapies, addressing key limitations of existing gene and DNA treatments, such as restricted access to diverse tissues and challenges with tolerability and genomic integration. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics aims to expand the scope of gene therapy beyond traditional gene replacement, enabling a broader range of applications across various medical fields, including genetic disorders, ophthalmology, oncology, and metabolic diseases. By focusing on cellular and tissue specificity, the company aspires to unlock new therapeutic possibilities for previously inaccessible conditions.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Private Equity Round in 2021
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
Capsule Corporation is an innovative online pharmacy established in 2015 and headquartered in New York, New York. It aims to transform the pharmacy industry by providing a streamlined and personalized experience for patients, healthcare providers, insurers, and manufacturers. Capsule's platform facilitates the online retail of pharmaceutical products through a user-friendly application that focuses on creating customized outcomes for its users. The company emphasizes the importance of human connection in healthcare, recognizing that behind the complexities of the system, there are individuals in need of care and support. Capsule has successfully raised significant funding from prominent investors, enabling it to further its mission of enhancing the pharmaceutical experience through technology and dedicated service.
Themis Solutions Inc. develops legal practice management and client intake software solutions for law firms. The company’s platforms are used for billing, case management, contact management, document management, calendaring, online payments, and time and expense tracking. The company was founded in 2007 and is based in Burnaby, Canada with additional offices in Toronto, Calgary, Canada; Santa Monica, California; and Dublin, Ireland.
Theseus Pharmaceuticals
Series B in 2021
Theseus Pharmaceuticals is a Technology based company.
Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics using CRISPR technology to address genetic disorders. Founded in 2017 and based in Berkeley, California, Scribe specializes in engineering CRISPR enzymes known as X-Editing (XE) molecules, which enhance the efficacy, specificity, and deliverability of genome editing compared to existing methods. The company's proprietary platform enables the creation of custom-engineered enzymes and delivery systems, facilitating precision targeting within the genome. Scribe Therapeutics aims to establish CRISPR-based therapies as a standard in clinical care, expanding access to transformative treatments for a wide range of conditions, including immuno-oncology and degenerative disorders. Through its commitment to overcoming the limitations of current genome editing technologies, Scribe Therapeutics is poised to make substantial contributions to human therapeutics.
Gyroscope is an ophthalmology company developing gene therapies for the treatment of eye diseases linked to an unbalanced complement system. Gyroscope was founded to explore the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD) and gene therapy as a mode of treatment delivery.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the drug development process through an asset-centric research and development model. The company advances a diverse portfolio of validated programs, each managed by a dedicated subsidiary and backed by a centralized infrastructure and experienced management team. Among its pipeline assets are SerpinPC, targeting Hemophilia A and B, LB101 for solid tumors, ORX750 for narcolepsy type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Additionally, Centessa is developing an undisclosed asset for solid tumors.
Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.
Design Therapeutics, Inc. is a clinical-stage biotechnology company based in Solana Beach, California, focused on developing innovative therapies for degenerative disorders resulting from nucleotide repeat expansions. Founded in 2017, the company is advancing its lead program aimed at treating Friedreich's ataxia, while also exploring treatment options for other conditions such as Fragile X syndrome and myotonic dystrophy. Design Therapeutics is known for its GeneTACTM molecules, a new class of small-molecule gene-targeted therapies designed to address the underlying causes of diseases linked to inherited nucleotide repeat expansion mutations. The company's ongoing research efforts seek to develop disease-modifying treatments for serious conditions driven by these genetic factors.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.
LianBio is a biopharmaceutical company based in Shanghai, China, with an additional office in Princeton, New Jersey. Founded in 2019, the company focuses on the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as other medical conditions. LianBio's mission is to enhance access to innovative medicines by partnering with leading organizations in the field to leverage advanced scientific discoveries. The company is dedicated to addressing unmet medical needs in Greater China and other Asian markets by in-licensing assets and building a diverse pipeline of clinically validated product candidates. Its portfolio aims to establish new standards of care across various therapeutic areas, including cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory conditions.
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
Private Equity Round in 2020
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
Flame Biosciences, Inc. is a clinical-stage biotechnology company based in New York that specializes in the research, development, and commercialization of innovative therapies targeting cancer and inflammatory diseases. Established in 2017, the company is advancing its FL-101 therapy, designed to treat lung cancers associated with inflammation, and FL-201, aimed at alleviating chronic inflammation in patients. By leveraging the emerging field of inflammasome science, Flame Biosciences seeks to provide effective treatments that enhance the quality of life for individuals affected by serious health conditions.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
Private Equity Round in 2020
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Allogene Therapeutics is a clinical-stage biotechnology company focused on immuno-oncology, particularly the development of genetically engineered allogeneic T cell therapies for cancer treatment. The company is advancing a pipeline of allogeneic T cell product candidates that leverage validated gene editing and proprietary cell manufacturing technologies. Key offerings include UCART19, which targets relapsed or refractory acute lymphoblastic leukemia, alongside several preclinical allogeneic CAR T therapies aimed at various malignancies and autoimmune diseases. By using T cells derived from healthy donors, Allogene Therapeutics aims to provide off-the-shelf treatment options that enhance patient eligibility and scalability. The company seeks to redefine CAR T therapy through its innovative approaches, addressing conditions like lymphoma, leukemia, and solid tumors.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Audentes Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases caused by single gene defects. The company is advancing several therapies, including AT132, currently in Phase I/II clinical trials for X-linked myotubular myopathy, and AT342, also in Phase I/II studies for Crigler-Najjar syndrome. Additionally, Audentes is exploring AT845 in preclinical studies for Pompe disease and AT307 for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. The company is also working on vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Collaborations include a partnership with Genethon for XLMTM treatments and an agreement with the University of Pennsylvania for Crigler-Najjar syndrome products. Founded in 2012 and headquartered in San Francisco, California, Audentes Therapeutics operates as a subsidiary of Astellas US Holding, Inc.
Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products.
AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine).
AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products.
AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
BeiGene, Ltd. is a biotechnology company engaged in the development and commercialization of targeted and immuno-oncology therapies for cancer. Founded in 2010 and based in Beijing, the company operates globally, focusing on addressing significant unmet medical needs across various cancer types. Its commercial portfolio includes treatments such as BRUKINSA for mantle cell lymphoma and Tislelizumab for Hodgkin's lymphoma, alongside other therapies for conditions like breast cancer and multiple myeloma. BeiGene's pipeline features several clinical-stage drug candidates, including Zanubrutinib, an inhibitor targeting Bruton's tyrosine kinase, and Pamiparib, a PARP inhibitor. The company is dedicated to making innovative cancer treatments more affordable and accessible, and it collaborates with various pharmaceutical firms to enhance its research and development efforts.
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. The company utilizes a unique platform based on live, attenuated bacteria engineered to deliver antigen/adjuvant fusion proteins, which aim to enhance the immune response against cancer. Advaxis is actively developing therapies for HPV-related cancers, including axalimogene filolisbac, currently in a Phase II clinical trial for head and neck cancer. Other products in development include ADXS-PSA for prostate cancer, ADXS-NEO for individualized treatment using neoantigens from a patient’s tumor, ADXS-HOT for generating robust anti-cancer immunity, and ADXS-HER2 targeting HER2-positive tumors. Advaxis has established collaborations and licensing agreements with various organizations to further advance its research and development efforts. The company was founded in 2002 and continues to progress its innovative treatments through multiple clinical trials.
Spark Therapeutics, Inc. is dedicated to developing gene therapy products aimed at treating debilitating genetic diseases. The company is known for LUXTURNA, a treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy, and has an extensive pipeline that includes candidates like SPK-8011 and SPK-8016 for hemophilia, SPK-7001 for choroideremia, and SPK-9001 for hemophilia B. Additionally, Spark is exploring liver-directed gene therapies such as SPK-3006 for Pompe disease and has programs targeting neurodegenerative diseases, including Huntington's disease and a form of Batten disease. Spark Therapeutics also engages in collaborations, notably with Pfizer for the SPK-FIX program for hemophilia B, and has a licensing agreement with Novartis for the commercialization of LUXTURNA outside the United States. Established in 2013 and based in Philadelphia, Spark Therapeutics operates as a subsidiary of Roche Holding AG and leverages a proprietary manufacturing platform to support its clinical studies across various therapeutic areas.
Private Equity Round in 2011
Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.
TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.
QuatRx Pharmaceuticals is a biopharmaceutical company based in Ann Arbor, Michigan, founded in 2000. The company focuses on discovering, licensing, developing, and commercializing therapeutic compounds, primarily in the fields of endocrine, metabolic, and cardiovascular health. One of its notable products is Osphena, which is used to treat vaginal atrophy, a condition commonly associated with estrogen deficiency in post-menopausal women. Through its commitment to addressing unmet medical needs, QuatRx Pharmaceuticals aims to advance healthcare solutions in its targeted therapeutic areas.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer.
FibroGen, Inc. is a biopharmaceutical company based in San Francisco, California, with additional offices in Beijing and Shanghai. The company specializes in discovering, developing, and commercializing therapeutics aimed at addressing serious unmet medical needs, particularly in the areas of anemia, fibrotic diseases, and cancer. Its lead product, Roxadustat, is an oral small-molecule inhibitor currently undergoing Phase III clinical trials for the treatment of anemia in chronic kidney disease in the United States and Europe, and is also being evaluated in China for myelodysplastic syndromes. Additionally, FibroGen is developing Pamrevlumab, a human monoclonal antibody that targets connective tissue growth factor, which is in Phase III trials for conditions such as idiopathic pulmonary fibrosis and pancreatic cancer, as well as in Phase II trials for Duchenne muscular dystrophy. The company has established collaboration agreements with partners like Astellas Pharma and AstraZeneca to enhance its research and development efforts.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.
It was founded in 2001 and headquartered in Mountain View, California.